Asthma: Current Treatments

Clinical Publishing, January 2007, Pages: 212

As the incidence of asthma in the adult population continues to increase, and the age of onset in children to decrease, this condition remains a primary concern not only for specialists in respiratory medicine, but also for physicians in many other fields, when dealing with the asthmatic patient. The range of therapeutic agents now available, and the diversity of targets on which they act, presents the doctor with a variety of options for managing the condition. In this volume leading international authorities explain the mechanisms of action of the drugs currently in use, and their clinical applications, singly and in combination. Asthma: Current Treatments provides physicians with a comprehensive resource that will help them evaluate for themselves the right approach for each of their patients. It will be of also be of interest to other health professionals involved in the care of patients being treated for this condition.

Benefits:

- Presents a comprehensive review of current treatment options
- Latest guidelines on clinical management reviewed from an international perspective
- Provides background on pharmacology and mechanisms of drug action
- Provides a key resource for individual patient care

Readership:

- Specialists in respiratory medicine, allergy and immunology
- General physicians
- Clinical pharmacologists
- Doctors in training

Editors
Contributors
Preface

Section I: First line anti-inflammatory and bronchodilator drugs

1 Novel mechanistic aspects of glucocorticosteroids in relation to asthma therapy
I. M. Adcock

2 Benefit–risk assessment of long-acting _-adrenergic and ultra long-acting-adrenergic agonists
M. Cazzola, J. Lötvall, M. G. Matera

3 Non-bronchodilator activities of _2-agonists
N. A. Hanania

4 The pros and cons of combination therapy
J. Lötvall

Section II: Novel approaches to bronchodilation

5 Controversies surrounding antileukotrienes
S. Salvi

6 The role of phosphodiesterase-4 inhibitors in asthma
G. P. Currie, D. K. C. Lee

7 Anticholinergic agents in asthma
J. Christian Virchow, M. Lommatzsch

Section III: Immunomodulation

8 Anti-IgE monoclonal antibody: a new era in the treatment of allergic asthma?
C. Oliveri, R. Polosa, G. D’Amato

9 New frontiers in allergen immunotherapy for asthma
R. Polosa

10 Role of CpG DNA in asthma
D. Gor, J. N. Kline

11 Putative role of antimicrobial activity in the treatment of asthma
P. Tarsia, S. Aliberti, M. Pappalettera, M. Zanardelli, F. Blasi

Section IV: Subphenotype centred therapy

12 What is new in the management of acute asthma?
G. J. Rodrigo

13 Airway disease, inflammometry and individualized treatment
P. K. Nair, F. E. Hargreave

14 Determinants of therapeutic response in asthma: cigarette smoking
M. Spears, R. Chaudhuri, N. C. Thomson

Abbreviations
Index

Edited by:

- R Polosa, Presidio Ospedaliero Ascoli-Tomaselli, Catania, Italy
- ST Holgate, Southampton General Hospital, Southampton, UK

Product Samples

A sample for this product is available. Please Login/Register to download this sample.

Customers who bought this item also bought

• Global Asthma Epidemiology and Patient Flow Analysis - 2012
• Epidemiology: Asthma – Stable prevalence rates in all age groups will lead to stable case numbers
• Asthma Therapeutics - Pipeline Assessment and Market Forecasts to 2018
• Asthma – Executive Market Summary 2011
• Asthma Global Clinical Trials Review, H1, 2012
• Market and Product Forecasts: Asthma - Premium products to offset loss to generics
• UK/Ireland Biotechnology Sector: Clinical Phase Drug Development Pipeline
• The Pricing and Reimbursement Environment for Respiratory Disease Therapies
• Asthma: An Atlas of Investigation and Management
• Asthma Global Clinical Trials Review, H2, 2011